Trade Summary

2 months ago, Lynx1 Capital Management LP, serving as 10% owner at Cullinan Therapeutics, Inc. (CGEM), purchased 165,667 shares at $8.40 per share, for a total transaction value of $1,391,686.00. Following this transaction, Lynx1 Capital Management LP now holds 8,963,500 shares of CGEM.

This purchase represents a 2.00% increase in Lynx1 Capital Management LP's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, October 28, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, October 30, 2025, 2 days after the trade was made.

Cullinan Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.